Evidence map›Paper›PMID 39598779›Full record

ArticleMolecules (Basel, Switzerland)2024

Epigallocatechin Gallate Enzymatic Alpha Glucosylation Potentiates Its Skin-Lightening Activity-Involvement of Skin Microbiota.

Cloé Boira, Emilie Chapuis, Laura Lapierre, Daniel Auriol, Cyrille Jarrin, Patrick Robe, Jean Tiguemounine, Amandine Scandolera, Romain Reynaud

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cloé BoiraGivaudan Active Beauty, R&D, 51110 Pomacle, France.ORCID 0000-0002-2870-198X
Emilie ChapuisGivaudan Active Beauty, R&D, 51110 Pomacle, France.
Laura LapierreGivaudan Active Beauty, R&D, 51110 Pomacle, France.
Daniel AuriolGivaudan Active Beauty, R&D, 31400 Toulouse, France.ORCID 0000-0002-1713-1176
Cyrille JarrinGivaudan Active Beauty, R&D, 31400 Toulouse, France.ORCID 0000-0001-9968-4227
Patrick RobeGivaudan Active Beauty, R&D, 31400 Toulouse, France.ORCID 0000-0002-9102-7801
Jean TiguemouninePolyclinique Courlancy, Surgery, 51100 Reims, France.
Amandine ScandoleraGivaudan Active Beauty, R&D, 51110 Pomacle, France.ORCID 0000-0001-6403-1664
Romain ReynaudGivaudan Active Beauty, R&D, 31400 Toulouse, France.ORCID 0000-0001-5417-5357

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Ultraviolet radiation takes part in photoaging and pigmentation disorders on skin. Epigallocatechin gallate (EGCG) is a well-known brightening and photoprotective compound but it faces limitations in terms of stability and solubility. (2) Methods: A more stable and water-soluble glucoside called EGCG-G1 was obtained by enzymatic glucosylation of EGCG. In vitro and ex vivo experiments evaluated EGCG-G1 skin penetration, antioxidant activity, and antimelanogenic properties compared to EGCG. This gene expression study characterized the pathways impacted by EGCG-G1. Four clinical studies covering phototypes I to V, at various ages, and different skin areas, using several tools, were conducted to assess the effect of EGCG-G1 on skin hyperpigmentation and tone. The impact of glucoside on skin microbiota, especially

Indexed as

AntioxidantsCatechinMicrobiotaSkinGlycosylationHumansSkin Lightening PreparationsSkin PigmentationAntioxidantsCatechinepigallocatechin gallateSkin Lightening PreparationsEGCGglucosideLactobacillusmelanogenesisphotoagingpigmentationtrigonelline

Identifiers

PMID39598779
PMCPMC11597265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.